MedPath

Antiepileptic Drugs in Elderly Patients

Recruiting
Conditions
Seizure, Epileptic
Interventions
Drug: antiepileptic drugs
Registration Number
NCT05459597
Lead Sponsor
Wei Zhao
Brief Summary

The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  1. Age ≥65 years old;
  2. Diagnosed with epilepsy;
  3. Using antiepileptic drugs for treatment;
Exclusion Criteria
  1. Patients who are expected to die within 48 hours;
  2. Patients with allergy to antiepileptic drugs;
  3. Patients receiving other investigational drugs;
  4. Other factors that the researcher considers unsuitable for inclusion.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Treatmentantiepileptic drugsThe use of antiepileptic drugs depends on the clinical practice.
Primary Outcome Measures
NameTimeMethod
The peak plasma drug concentration of antiepileptic drugs.at (0-4) h after oral administration

To detect the peak plasma drug concentration of antiepileptic drugs.

The random plasma drug concentration of antiepileptic drugs.at (4-10) h after oral administration

To detect the random plasma drug concentration of antiepileptic drugs.

The trough plasma drug concentration of antiepileptic drugs.at (1-2) h before the next administration

To detect the trough plasma drug concentration of antiepileptic drugs.

Secondary Outcome Measures
NameTimeMethod
The frequency of seizuresThrough study completion, an average of 14 days
The incidence of adverse drug reactionThrough study completion, an average of 14 days

Trial Locations

Locations (1)

Wei Zhao

🇨🇳

Jinan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath